Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
PHARMA JONPI .: 08/24/14
Puma – PHARMA
Puma Biotechnology Surging
Puma Pharma (@PumaPharma) / Twitter
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma – PHARMA
Medical Affairs eLearning - MSL Society
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology, Inc. | LinkedIn
Puma – PHARMA
Puma Biotechnology
Puma – PHARMA
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Men – PHARMA
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire